Genmab A/S reports Phase 3 lymphoma PFS result
Genmab A/S and AbbVie reported a 51% reduction in progression or death risk in a Phase 3 trial of epcoritamab plus R-CHOP for high-risk lymphoma patients. The study met its primary endpoint with a hazard ratio of 0.49. Genmab's shares rose 10.73% on the news. The companies plan to consult regulators and present data at a medical meeting.
How this was made
The 30-second read
Why it matters
The 49% hazard ratio (HR 0.49) with p < 0.0001 signals a strong efficacy signal, prompting immediate market reaction.
Market read
Topline Phase 3 data creates a catalyst for both partners, driving short‑term price spikes and potential pipeline expansion.
What to watch
Regulatory timeline and reimbursement uncertainty may temper long‑term upside.
Background
Phase 3 EPCORE DLBCL‑2 trial compared epcoritamab + R‑CHOP vs R‑CHOP alone in newly diagnosed diffuse large B‑cell lymphoma.
Ticker impact
Genmab reported Phase 3 topline data showing 51% risk reduction, shares jumped 10.7% pre‑market.
upward pressure as market prices in the efficacy breakthrough
Topline efficacy data is new, material and has already moved the stock sharply.
AbbVie co‑reported the same Phase 3 results; shares rose alongside Genmab.
upward pressure as investors value the expanded pipeline
Joint positive data adds to AbbVie's oncology portfolio, prompting immediate price gain.
Market effects
Biotech sector may see broader rally on positive lymphoma data.
European biotech (Genmab) gains visibility; US market reacts to AbbVie partnership.
First‑line lymphoma breakthrough could influence global oncology pipelines.
Counterpoint
If later data reveal safety concerns, the rally could reverse.
Key entities
- companyGenmab A/S
Copenhagen‑based antibody developer, US‑listed via GMAB.
- companyAbbVie Inc.
US pharmaceutical company, ticker ABBV.
